Fundraising FoxAisling Capital — 2017 Investments
5 investments dated 2017 · listed companies and verified rows first · show all
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)inRandal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)inLee Bendekgey(Executive Officer)inGeoffrey Crouse(Director)
Board seatEric Aguiar· per SEC Form D
Co-investorsCivilization Ventures Management, LlcDecheng CapitalFifty YearsManta Ray VenturesOberland CapitalPrefix Capital+4 more
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)inJoseph P Slattery(Executive Officer)inJames J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)
Board seatAftab Kherani· per SEC Form D
Co-investorsHercules Capital, Inc.Saints CapitalSV Health InvestorsQuaker BioVenturesSV Life Sciences
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAlexandriaBezos ExpeditionsBlue Pool Capital+7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Bristol Myers SquibbMenlo Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.